Eikon Therapeutics, Inc. (EIKN) stock
EIKNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026
$5.15−0.23 (-4.36%)
Close on Nov 17, 2026Market cap $278.95MP/E –Yield –
Eikon Therapeutics enterprise value
Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.
Eikon Therapeutics's enterprise value was -$170.00M on Nov 11, 2026.
Enterprise Value at the end of each year
| Period | Period end | Value | Change |
|---|---|---|---|
| 2026 | Nov 11, 2026 | -$170.00M | – |
See a number that looks wrong?